The purpose of this study is to compare the effectiveness of Nivolumab, Ipilimumab and Sargramostim vs Nivolumab and Ipilmumab. You must be diagnosed with unresectable stage 3 or stage 4 melanoma.
Contact phone
Carolyn Krahulik | 517.364.2811
Contact email
cancerclinicaltrials@sparrow.org
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Melanoma
Webform